ArticleNAR molecular medicine2026
Human pneumovirus induces IFN-dependent expression of the immune-responsive gene 1 and is inhibited by 4-octyl itaconate in human macrophages.
Article in NAR molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The immunometabolite itaconate, generated by immune-responsive gene 1 (IRG1/ACOD1), and its derivative 4-octyl itaconate (4OI) have been found to modulate inflammation and progression of viral infections, but their effects on the significant respiratory pathogen human metapneumovirus (HMPV) is unknown. Here, we demonstrate that HMPV induces IRG1 expression via a TANK-binding kinase 1, NF-κB-, and interferon (IFN)-dependent manner in human primary macrophages. We further show that the addition of a cell-permeable derivative of itaconate, 4OI, but not itaconate itself or its natural isomer citraconate, reduces HMPV and IFN-β levels in human macrophages. 4OI additionally activated Nrf2, while Nrf2 depletion enhanced HMPV levels, suggesting that Nrf2 mediates the antiviral effect of 4OI on HMPV. Also, we found that 4OI reduced expression of ATP-dependent citrate lyase, a lipid metabolic enzyme that supports HMPV replication. Our study suggests 4OI as a potential compound for targeting HMPV-IFN-β-driven disease and highlights Nrf2-dependent lipid reprogramming as a potential modulator of 4OI antiviral effects.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.